OPTH Optimi Health Corp

$OPTH ADDS MORE EXPERIENCE TO THE BOARD Optimi Health appointed Melanie Pump to its Board of Directors, bringing 25+ years of senior finance and leadership experience. ▫️ 25+ years in finance and corporate leadership ▫️ 20+ years working with public companies ▫️ Currently CFO of Qu Data Centres ▫️ Experience across technology, fintech and high growth companies ▫️ OPTH is advancing a Phase 2 psilocybin trial for up to 200 patients and a Phase 3 MDMA trial for up to 100 patients More financial and governance experience being added as OPTH continues building out its clinical and commercial strategy. Sector Peers: $CMPS $ATAI $GHRS

$OPTH — 4.5M float. The weekly coil is tight. Licensed psychedelic manufacturer. Health Canada drug licence. cGMP plant in B.C. Already shipping 5mg psilocybin to Australia for treatment-resistant depression — prescribed and reimbursed. Phase 2 psilocybin for major depression, up to 200 patients. Phase 3 MDMA for PTSD, up to 100 veterans. One batch feeds the trial and the clinics. Cap $28M. Float ~4.5M. Next print Dec 11. Weekly: highs $9.98 / $8.84, washed to $4.00. Rising line meeting a shelf at $5.15–$5.20. Sitting at $4.83. Measured move +88% toward ~$9. $4.00 cannot go. Weekly close over $5.20 opens $6.65 / $8.40. Supply is running. Trials are authorized. Float is 4.5M. $5.20 is the ask.

$OPTH NEWS 🗞️ Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply "Since 2025, Optimi has supplied this psilocybin product commercially to licensed clinics in Australia, where it is prescribed and reimbursed for treatment-resistant depression," said Dane Stevens, Optimi Chief Executive Officer and Co-Founder. "We are excited to be collecting our own clinical data on the same product in our Health Canada-approved Phase 2 clinical trial for major depressive disorder." One batch supplies both Canadian trial and Australian clinics. Positive results could lead to eventual commercialization in Canada.